A clustering and graph deep learning-based framework for COVID-19 drug repurposing

TL;DR

This paper introduces a novel unsupervised graph autoencoder framework that clusters heterogeneous drug data to identify promising candidates for COVID-19 drug repurposing, based solely on reported drug properties and interactions.

Contribution

The study presents a new graph-based autoencoder approach for clustering multi-feature drug data to aid in COVID-19 drug repurposing, leveraging only publicly available drug information.

Findings

Identified three key drug clusters related to COVID-19.

Recommended top 15 drugs for COVID-19 repurposing based on clustering.

Framework successfully highlights drugs under clinical trials for COVID-19.

Abstract

Drug repurposing (or repositioning) is the process of finding new therapeutic uses for drugs already approved by drug regulatory authorities (e.g., the Food and Drug Administration (FDA) and Therapeutic Goods Administration (TGA)) for other diseases. This involves analyzing the interactions between different biological entities, such as drug targets (genes/proteins and biological pathways) and drug properties, to discover novel drug-target or drug-disease relations. Artificial intelligence methods such as machine learning and deep learning have successfully analyzed complex heterogeneous data in the biomedical domain and have also been used for drug repurposing. This study presents a novel unsupervised machine learning framework that utilizes a graph-based autoencoder for multi-feature type clustering on heterogeneous drug data. The dataset consists of 438 drugs, of which 224 are under clinical trials for COVID-19 (category A). The rest are systematically filtered to ensure the safety and efficacy of the treatment (category B). The framework solely relies on reported drug data, including its pharmacological properties, chemical/physical properties, interaction with the host, and efficacy in different publicly available COVID-19 assays. Our machine-learning framework reveals three clusters of interest and provides recommendations featuring the top 15 drugs for COVID-19 drug repurposing, which were shortlisted based on the predicted clusters that were dominated by category A drugs. The anti-COVID efficacy of the drugs should be verified by experimental studies. Our framework can be extended to support other datasets and drug repurposing studies, given open-source code and data availability.